# Bioequivalence of Alprazolam Sublingual vs Oral Tablets

> **NCT00860119** · PHASE1 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 23 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** alprazolam sublingual tablet
- **DRUG:** alprazolam oral tablet

## Key facts

- **NCT ID:** NCT00860119
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2021-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00860119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00860119, "Bioequivalence of Alprazolam Sublingual vs Oral Tablets". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00860119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*